New hope for stronger bones in young women with Stress-Induced missed periods
NCT ID NCT06533865
Summary
This study is testing whether adding a bone-building medication called romosozumab to standard hormone replacement helps improve bone density in young women (ages 14-30) with functional hypothalamic amenorrhea (FHA). FHA is when periods stop due to high stress, intense exercise, or eating disorders, and it often leads to low bone density. Participants will be randomly assigned to receive either romosozumab or a placebo injection for 6 months, while all receive standard estrogen/progesterone therapy and a one-time bone-strengthening infusion at 6 months. The main goal is to see if the romosozumab group shows greater improvement in spine and leg bone strength after one year compared to the placebo group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FHA (FUNCTIONAL HYPOTHALAMIC AMENORRHEA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Medical Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.